


Searching News Database: Intrexon
HSMN NewsFeed - 2 Sep 2020
NeuroBo Pharmaceuticals Appoints Douglas J. Swirsky to the Board of Directors
NeuroBo Pharmaceuticals Appoints Douglas J. Swirsky to the Board of Directors
HSMN NewsFeed - 20 Dec 2018
Merck KGaA, Darmstadt, Germany, Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon
Merck KGaA, Darmstadt, Germany, Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon
HSMN NewsFeed - 12 Sep 2018
Sutro Taps Worsley as Chief Business Officer; Names Fitzpatrick as People and Communications Chief
Sutro Taps Worsley as Chief Business Officer; Names Fitzpatrick as People and Communications Chief
HSMN NewsFeed - 5 Dec 2017
Cocoon Biotech Appoints Dr. Annalisa Jenkins as Executive Chair of the Board
Cocoon Biotech Appoints Dr. Annalisa Jenkins as Executive Chair of the Board
HSMN NewsFeed - 11 May 2016
Isaac J. Bright, MD, Joins Synthetic Biologics as Vice President, Corporate Development
Isaac J. Bright, MD, Joins Synthetic Biologics as Vice President, Corporate Development
HSMN NewsFeed - 9 May 2016
Synthetic Biologics Appoints Deb Mathews, PharmD, as Vice President, Medical Affairs
Synthetic Biologics Appoints Deb Mathews, PharmD, as Vice President, Medical Affairs
HSMN NewsFeed - 1 Oct 2015
Synthetic Biologics Appoints Raymond Stapleton, PhD, as Senior Vice President, Manufacturing
Synthetic Biologics Appoints Raymond Stapleton, PhD, as Senior Vice President, Manufacturing
HSMN NewsFeed - 15 Jul 2015
Histogenics Corporation Announces Dr. Gloria Matthews as Chief Medical Officer
Histogenics Corporation Announces Dr. Gloria Matthews as Chief Medical Officer
HSMN NewsFeed - 22 Jun 2015
Histogenics Corporation Announces Appointment of New Chief Financial Officer
Histogenics Corporation Announces Appointment of New Chief Financial Officer
HSMN NewsFeed - 2 Jun 2015
ZIOPHARM Announces Caesar J. Belbel, Chief Legal Officer, Appointed Chief Operating Officer
ZIOPHARM Announces Caesar J. Belbel, Chief Legal Officer, Appointed Chief Operating Officer
HSMN NewsFeed - 24 Nov 2014
Agilis Biotherapeutics Names Former Shire Executive Dr. Gregory Robinson as Chief Scientific Officer
Agilis Biotherapeutics Names Former Shire Executive Dr. Gregory Robinson as Chief Scientific Officer
HSMN NewsFeed - 23 Sep 2014
Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development
Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development
HSMN NewsFeed - 6 Jan 2014
Fibrocell Science Appoints Robert Sheroff, Vice President of Technical Operations
Fibrocell Science Appoints Robert Sheroff, Vice President of Technical Operations
HSMN NewsFeed - 31 Dec 2013
Agilis Biotherapeutics Completes $8 Million Financing to Develop DNA-based Therapeutics for Rare Diseases
Agilis Biotherapeutics Completes $8 Million Financing to Develop DNA-based Therapeutics for Rare Diseases
HSMN NewsFeed - 21 Oct 2013
Soligenix Announces Appointment of Marco Maria Brughera to its Board of Directors
Soligenix Announces Appointment of Marco Maria Brughera to its Board of Directors
HSMN NewsFeed - 3 Oct 2013
Soligenix Appoints Oreola Donini, PhD, as Vice President of Preclinical Research and Development
Soligenix Appoints Oreola Donini, PhD, as Vice President of Preclinical Research and Development
HSMN NewsFeed - 16 Sep 2013
FDA Grants Soligenix Orphan Drug Designation for SGX94 for Treatment of Acute Radiation Syndrome
FDA Grants Soligenix Orphan Drug Designation for SGX94 for Treatment of Acute Radiation Syndrome
HSMN NewsFeed - 26 Mar 2013
ZIOPHARM Terminates Development of Palifosfamide in Metastatic Soft Tissue Sarcoma
ZIOPHARM Terminates Development of Palifosfamide in Metastatic Soft Tissue Sarcoma
HSMN NewsFeed - 30 Jan 2012
ImmunoGen, Inc. Announces Addition of Kristine Peterson and Dean Mitchell to Its Board of Directors
ImmunoGen, Inc. Announces Addition of Kristine Peterson and Dean Mitchell to Its Board of Directors
HSMN NewsFeed - 18 Oct 2011
Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial
Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial
